[{"address1": "2225 East Bayshore Road", "address2": "Suite 200", "city": "Palo Alto", "state": "CA", "zip": "94303", "country": "United States", "phone": "844-200-2826", "website": "https://www.cantabio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an A\u00df targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Gergely  Toth", "age": 49, "title": "Founder, CEO, President & Director", "yearBorn": 1974, "fiscalYear": 2018, "totalPay": 157000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas Roger Sawyer M.B.A., Ph.D.", "age": 53, "title": "CFO & Director", "yearBorn": 1970, "fiscalYear": 2018, "totalPay": 109000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bal\u00e1sz  Herberth", "title": "Head of Cell Biology & In Vitro Pharmacology", "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1546214400, "maxAge": 86400, "priceHint": 4, "open": 1.01, "dayLow": 1.01, "dayHigh": 1.01, "regularMarketOpen": 1.01, "regularMarketDayLow": 1.01, "regularMarketDayHigh": 1.01, "beta": 0.12, "volume": 46, "regularMarketVolume": 46, "marketCap": 563600, "fiftyTwoWeekLow": 1.01, "fiftyTwoWeekHigh": 1.01, "fiftyDayAverage": 1.01, "twoHundredDayAverage": 1.01, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 1148188, "floatShares": 7782, "sharesOutstanding": 22544, "heldPercentInsiders": 0.70008004, "bookValue": -97.77, "lastFiscalYearEnd": 1522454400, "nextFiscalYearEnd": 1553990400, "mostRecentQuarter": 1546214400, "netIncomeToCommon": -1543113, "trailingEps": -8.08, "lastSplitFactor": "1:5000", "lastSplitDate": 1560988800, "exchange": "OEM", "quoteType": "EQUITY", "symbol": "CTBO", "underlyingSymbol": "CTBO", "shortName": "CANTABIO PHARMACEUTICALS INC", "longName": "Cantabio Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1447684200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c5fa4a7c-7ef2-38ad-9e58-dbe1cace1b39", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.01, "recommendationKey": "none", "totalCash": 283371, "totalCashPerShare": 12.569, "totalDebt": 1408789, "quickRatio": 0.128, "currentRatio": 0.147, "returnOnAssets": -4.70974, "freeCashflow": -217402, "operatingCashflow": -798403, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]